Semiquantitative CLDN18 expression and clinical outcomes in patients with CLDN18-positive gastric cancer treated with zolbetuximab plus chemotherapy

Key Points

• CLDN18 expression correlates with improved clinical outcomes in gastric cancer patients.
• Patients with higher CLDN18 positivity showed better responses to zolbetuximab and chemotherapy.
• Assessment used a semiquantitative approach to measure CLDN18 levels across various clinical settings.
• Highlights the need for further studies to validate these findings in larger cohorts.